Professor Sir Munir Pirmohamed
NHS Chair of Pharmacogenetics, University of Liverpool
Director of the Wolfson Centre for Personalised Medicine and MRC Centre for Drug Safety Sciences
Commissioner on Human Medicines (CHM) | UK
Creating tomorrow's drug discovery toolbox
Join us to hear scientific leaders explore how these advances are being used to identify new drug targets and create opportunities for improved pre-clinical work and clinical trials design.
“Outstanding presenters and presentations. Great balance of strategic direction and practical impact. Thought provoking and insightful, and from a number of different perspectives. Quality of presenters, panel discussions, facilitators universally excellent.”
29 – 30 APRIL 2024
Welcome dinner and early registration available on Sunday 28 April.
Hinxton Hall Conference Centre
Wellcome Genome Campus
Hinxton, UK. CB10 1RQ
OR online via our conference portal
Registration is now closed
Abstracts for consideration for poster presentations can be submitted during registration.
Academic discounts available
Talks
NHS Chair of Pharmacogenetics, University of Liverpool
Director of the Wolfson Centre for Personalised Medicine and MRC Centre for Drug Safety Sciences
Commissioner on Human Medicines (CHM) | UK
CEO, Think 10
Formerly CEO, LifeArc | UK
Early-bird registration opens
Early bird registration deadline
Poster Submission closes
In person registration closes
Notification of poster acceptance
Virtual registration closes
AstraZeneca has provided a sponsorship grant towards this independent Programme
Both audiences, face-to-face and virtual, will experience presentations from our esteemed panel of speakers, participate in live Q&A and panel discussion sessions, take advantage of networking opportunities, poster sessions, vendor exhibitions and on-demand materials.
This meeting will focus on ground-breaking advances in genomics for target choice, in vitro technologies, novel modalities, risk mitigation, data analysis, AI/ML, digital health, and how they could radically increase the discovery of disease relevant biological targets and the development of new drugs.
Participants from industry, academia and government interested in challenging the existing approaches to target selection and translation are encouraged to attend, and set the agenda for the next era of drug discovery.
Abstracts for consideration for poster presentations can be submitted during registration.
GSK, UK
NPL, UK
GSK, UK
Imperial College London, UK
AstraZeneca has provided a sponsorship grant towards this independent Programme
NHS Chair of Pharmacogenetics, University of Liverpool
Director of the Wolfson Centre for Personalised Medicine and MRC Centre for Drug Safety Sciences
Commissioner on Human Medicines (CHM) | UK
CEO, Think 10
Formerly CEO, LifeArc | UK
Director
Open Targets | UK
Senior Director
GSK Cellzome | Germany
Computational Health Center
HelmholtzAI | Germany
Chief Scientific Officer
Emulate Inc. | UK
Richard Dimbleby Chair of Cancer Research, King’s College London
Vice President and Head of Oncology Translational Research, GSK | UK
Centre for Predictive in vitro Models
Queen Mary University of London | UK
Senior Director, Early Oncology
AstraZeneca | UK
Chief Scientific Officer
Proxygen | Austria
Chief Scientific Officer
Arvinas | UK
CEO,
Etheros Pharmaceuticals Corp. | UK
Professor for Life Science Management
THI Business School Ingolstadt | Germany
Decision Analyst
GSK, UK
Emerging Leader
UK DRI
Head of Cheminformatics & Data Science
GSK | UK
Vice President of AI
BenevolentAI | UK
Abstracts should be submitted during registration.
Deadline for poster submissions: 1 April 2024
Notification of poster acceptance: 15 April 2024
For any questions about the registration process or event logistics, do not hesitate to contact:
This workshop will be held at: Hinxton Hall Conference Centre, Wellcome Genome Campus, CB10 1RQ.
Set within a one hundred acre estate bordering the River Cam, Hinxton Hall Conference Centre is located on the Wellcome Genome Campus, alongside research institutions that are at the forefront of the genomics revolution.
Contact the Wellcome Genome Campus to enquire about the availability for any remaining rooms on site.
Reception Team on +44 (0)1223 495000 or at conference.reception@hinxtonhall.org
For more information visit the Hinxton Hall website.
Registration is now closed. Access to the conference portal has now been sent to all registered attendees attending in person and online, get in touch with us if you have registered but not received the details.
Early bird in person: £225
Early bird virtual: £225
Standard in person: £275
Standard virtual: £275
Student rate: £110*
Academic rate: £150
Conference dinner: £25
*Limited places available, in person attendance only
Amex payments not accepted
The full conference programme:
Monday 29 – Tuesday 30 April 2024
Optional welcome dinner and drinks, and early registration on Sunday 28 April (for in person attendees)
Live and recorded presentations
Panel discussions
Live Q&A
poster sessions
Access to our vendor exhibition
Networking opportunities
Access to dedicated on-line conference portal and on-demand materials
Registration for delegates attending in person closes 18 April 2024
Registration for delegates attending virtually closes 22 April 2024
Discounts are available for students and delegates from academic organisations
If you require a letter of invitation for a visa application, please contact:
targettopatient@ebi.ac.uk
For help with meeting registration, please contact: targettopatient@ebi.ac.uk
We particularly welcome exhibitors relevant to any of the sessions or the strategic aims of the overall conference, which attracts life scientists from academia, the bitotech/pharma industry and policy makers interested in emerging approaches to drug discovery and deployment for the next decade and beyond.
The exhibitor area is being supported by ELRIG, the leading European not-for-profit organization providing scientific content and exhibition events at life science conferences.
For more, information on exhibitor packages available, please contact Tara Shanks at ELRIG.
AstraZeneca has provided a sponsorship grant towards this independent Programme